The company is to start a pivotal Chinese trial of its PD-1 x TGF-β-targeting fusion protein.

The latest first-in-human entrants include an anti-TROP2 ADC from Jiangsu Hansoh and a mystery bispecific from Johnson & Johnson.

Novartis looks set to hand nisevokitug rights back to Xoma, though plenty of work on TGF-β continues.